Evidence map›Paper›PMID 32571276›Full record

ArticleBMC urology2020

Physician preferences for non-metastatic castration-resistant prostate cancer treatment.

Sandy Srinivas, Ateesha F Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Erica Horodniceanu, A Reginald Waldeck, Stacey J Simmons

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sandy SrinivasStanford University Medical Center, Palo Alto, California, USA. sandysri@stanford.edu.
Ateesha F MohamedBayer U.S. LLC, Whippany, NJ, USA.
Sreevalsa AppukkuttanBayer U.S. LLC, Whippany, NJ, USA.
Marc BottemanPharmerit International, Bethesda, MD, USA.
Xinyi NgPharmerit International, Bethesda, MD, USA.
Namita JoshiPharmerit International, Bethesda, MD, USA.
Erica HorodniceanuPharmerit International, Bethesda, MD, USA.
A Reginald WaldeckBayer U.S. LLC, Whippany, NJ, USA.
Stacey J SimmonsBayer U.S. LLC, Whippany, NJ, USA.
Bayer (United States) · USPharmerit (United States) · USStanford Medicine · US

Funding

Bayer US LLC NA
6 · The paper itself

Abstract

backgroundRecent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to explore how United States physicians make treatment decisions between adverse events (AEs) and survival gains in nmCRPC, a largely asymptomatic disease.

methodsTreating physicians (n = 149) participated in an online survey that included 14 treatment choice questions, each comparing 2 hypothetical treatment profiles, which varied in terms of 5 safety and 2 efficacy attributes. We described safety attributes (fatigue, skin rash, cognitive problems, falls, and fractures) in terms of severity and frequency, and efficacy attributes (overall survival [OS] and time to pain progression) in terms of duration of effect. We used a random parameters logit model to estimate preference weights and importance scores for each attribute. We also estimated the amount of survival gain physicians were willing to trade for a reduction in specific AEs between treatment options.

resultsPhysicians placed more importance on survival than on time to pain progression, and viewed a reduction in cognitive problems from severe to none, a reduction in risk of a serious fracture from 8% to none, and a reduction in fatigue from severe to none as the most important safety attributes. Physicians were willing to forego 9.1 and 6.6 months of OS, respectively, to reduce cognitive problems and fatigue from severe to mild-to-moderate. To reduce the risk of a serious fracture from 8 to 5% and 5% to none, physicians were willing to trade 3.9 and 5.3 months of OS, respectively.

conclusionsPhysicians were willing to trade substantial amounts of survival to avoid AEs between hypothetical treatments. These results emphasize the importance of carefully balancing therapies' benefits and risks to ultimately optimize the overall quality of nmCRPC patients' survival. Nonetheless, it is noted that the results from the study sample of 149 physicans may not be representative of the viewpoints of all nmCRPC-treating physicians.

Indexed as

Attitude of Health PersonnelPractice Patterns, Physicians'UrologyAndrogen Receptor AntagonistsHumansMaleProstatic Neoplasms, Castration-ResistantSurvival RateAndrogen Receptor AntagonistsCastration-resistantChoice behaviorPhysiciansProstatic neoplasmsRisk assessment

Identifiers

PMID32571276
PMCPMC7310549
OpenAlexW3036384609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.